麴菌病市場 - 全球產業規模、佔有率、趨勢、機會、預測：按類型、藥物類型、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

全球麴菌症市場預計將從 2025 年的 47.3 億美元成長到 2031 年的 59.9 億美元，複合年成長率為 4.01%。

該市場涵蓋用於識別和治療曲霉菌感染疾病的診斷技術和抗真菌藥物療法。主要成長要素來自全球免疫力缺乏人群的不斷增加，例如器官移植受者和癌症化療患者，他們容易罹患嚴重的真菌感染疾病。根據全球真菌感染疾病行動基金估計，到2024年，全球慢性肺麴菌症病病例數將達到180萬例，確保了對有效治療方法和精準診斷的穩定需求。然而，日益嚴重的抗生素抗藥性問題對市場擴張構成重大障礙。對標準Azole藥物治療無效的曲霉菌株的日益增多，使臨床治療更加複雜，並迫使人們使用替代藥物，而這些藥物通常毒性高且昂貴。這種抗藥性為製藥公司帶來了監管和研發方面的挑戰，限制了一線療法的廣泛應用，並阻礙了整體市場成長。

市場促進因素

推動市場發展的關鍵因素包括新型抗真菌療法研發管線的擴張和策略合作，而這一切都源自於對抗多重抗藥性真菌菌株的迫切需求。製藥研發公司正不斷籌集大量資金籌措，以推進新型藥物（例如奧羅托米德）的後期臨床試驗，這些藥物具有對抗抗藥性真菌的替代作用機制。例如，F2G公司於2024年9月成功資金籌措了1億美元，用於支持其新型抗真菌藥物ororofim的監管核准和商業化。這凸顯了業界為克服現有Azole治療方法的局限性並確保創新治療方法的穩定供應所做的努力。同時，高風險患者族群中侵襲性麴菌病發生率的上升也顯著擴大了市場的商業性範圍。抑制免疫功能的現代醫療干預措施導致這些嚴重感染疾病的盛行率激增，因此需要積極且昂貴的抗真菌治療。根據國際感染疾病學會 (ISID) 於 2024 年 9 月發布的最新全球預測，侵襲性麴菌症的年病例數將超過 210 萬例。日益加重的疾病負擔直接推動了現有藥物療法的產生收入。例如，巴塞爾製藥公司 (Basilea Pharmaceuticals) 的抗真菌藥物Crescentba 在截至 2024 年 3 月的 12 個月內，全球市場銷售額達到 4.89 億美元，這反映出市場對有效治療方法的迫切需求。

市場挑戰

抗生素抗藥性問題日益嚴重，成為阻礙全球麴菌症市場成長的主要障礙。對標準Azole藥物治療無效的曲霉菌株的日益增多，迫使臨床醫生放棄一線治療，轉而採用通常價格更高、毒性更大的二線療法。這種轉變使病患管理更加複雜，加重了醫療系統的經濟負擔，並阻礙了標準抗真菌藥物療法的順利推廣。此外，抗藥性的蔓延導致市場波動，製藥公司在推出新的抗真菌藥物時面臨更高的研發風險和更嚴格的監管審查。近期統計數據凸顯了這一障礙的嚴重性，揭示了抗藥性病例令人擔憂的普遍性。根據美國疾病管制與預防中心（CDC）估計，到2024年，某些地區醫療機構中發生的煙曲霉感染疾病中，約有19%對Azole抗真菌藥物抗藥性。相當一部分抗藥性感染疾病導致現有治療方法對很大一部分患者無效，直接阻礙了市場擴張。因此，市場分散，現有治療方法的整體普及速度也受到影響。

市場趨勢

快速、非侵入性診斷技術的日益普及正在改變臨床診療流程，減少了支氣管鏡檢查和肺部切片檢查等侵入性操作的需求。臨床醫師正逐步引入尿液抗原檢測，以縮短侵襲性麴菌症的診斷時間。這一趨勢在骨髓惡性腫瘤患者中尤其顯著，因為快速診斷對患者的生存率至關重要。這項技術進步克服了傳統培養方法和血清生物標記的局限性，這些方法往往會導致結果延遲且不明確，從而提供了一種對患者友好的替代方案，能夠實現早期治療性介入。 Pearl Diagnostics公司的新產品MycoMEIA曲霉菌檢測試劑盒於2025年8月獲得FDA核准，其臨床檢驗顯示靈敏度約為90%，為提高疾病檢出率提供了準確、非侵入性的工具。同時，針對高風險移植患者，預防性抗黴菌治療的趨勢也顯著增強，旨在症狀出現前預防感染疾病。藥廠正積極拓展長效棘白菌素類藥物和其他新型藥物的適應症，將其應用於異體造血幹細胞移植患者的預防性治療，因此超越被動治療策略。這種預防性方法具有顯著的經濟和臨床價值，因為它能夠預防免疫力缺乏患者發生嚴重真菌感染疾病，從而縮短住院時間並降低全身毒性。 CorMedix公司在2025年8月收購Melinta Therapeutics後，預計其抗真菌藥物rezafungin在擴展的預防性治療領域的年銷售額高峰將超過2億美元，這印證了市場對預防醫學的強勁需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球麴菌病市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（慢性肺部麴菌症、過敏性支氣管肺麴菌症(ABPA)、侵襲性麴菌症）
  • 藥物類型（Isavuconazole、Voriconazole、Amphotericin B、Itraconazole、皮質類固醇、Posaconazole、其他）
  • 給藥途徑（口服、靜脈注射）
  • 分銷通路（醫院藥局、零售藥局、網路藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美麴菌病市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲麴菌病市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區麴菌病市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲麴菌病市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲麴菌病市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球麴菌病市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Pfizer Inc.
• Merck & Co., Inc.
• Astellas Pharma Inc.
• Gilead Sciences, Inc.
• Bayer AG
• Novartis AG
• Bristol-Myers Squibb Company
• Basilea Pharmaceutica Ltd.
• F2G Ltd.
• Mayne Pharma Group Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Aspergillosis Market is projected to expand from USD 4.73 Billion in 2025 to USD 5.99 Billion by 2031, exhibiting a Compound Annual Growth Rate (CAGR) of 4.01%. This market encompasses diagnostic technologies and antifungal pharmacotherapies used for identifying and treating infections caused by Aspergillus mold species. A primary growth driver is the increasing global population of immunocompromised individuals, such as organ transplant recipients and cancer chemotherapy patients, who are highly susceptible to severe fungal diseases. With an estimated 1.8 million annual global cases of chronic pulmonary aspergillosis in 2024, as reported by the Global Action Fund for Fungal Infections, a consistent demand for effective treatments and accurate diagnostics is assured.However, market expansion faces a significant hurdle due to the escalating issue of antimicrobial resistance. The growing prevalence of Aspergillus strains unresponsive to standard azole-based treatments complicates clinical management and necessitates the use of alternative drugs, which often carry higher toxicity or costs. This resistance profile creates regulatory and developmental obstacles for pharmaceutical companies, limiting the widespread adoption of first-line therapies and hindering the market's overall growth.

Market Driver

A key market driver is the expanding pipeline of novel antifungal therapeutics and strategic collaborations, driven by the critical need to combat multi-drug resistant fungal strains. Pharmaceutical developers are increasingly securing substantial funding to advance late-stage clinical trials for new drug classes, such as orotomides, which offer alternative mechanisms of action against resistant molds. For instance, F2G secured $100 million in September 2024 to support the regulatory approval and commercialization of its novel antifungal agent, olorofim, highlighting the industry's dedication to overcoming limitations of current azole-based therapies and ensuring a steady flow of innovative treatments.Concurrently, the rising incidence of invasive aspergillosis among high-risk patient groups is significantly broadening the market's commercial scope. The prevalence of these severe infections has surged due to modern medical interventions that suppress immune function, necessitating aggressive and costly antifungal management. Updated global estimates from the International Society for Infectious Diseases in September 2024 indicated over 2.1 million annual cases of invasive aspergillosis. This increasing disease burden directly boosts revenue generation for established pharmacotherapies, as evidenced by Basilea Pharmaceutica's antifungal Cresemba reaching $489 million in total global in-market sales for the twelve-month period ending March 2024, reflecting the urgent demand for effective treatment options.

Market Challenge

The escalating problem of antimicrobial resistance presents a formidable challenge that impedes the growth of the Global Aspergillosis Market. The increasing prevalence of Aspergillus strains unresponsive to standard azole-based treatments compels clinicians to forsake first-line therapies in favor of second-line alternatives, which are frequently more costly and linked to greater toxicity. This shift complicates patient management and elevates the economic burden on healthcare systems, thereby stifling the smooth integration of standard antifungal pharmacotherapies. Furthermore, the proliferation of resistance introduces market volatility, as pharmaceutical companies encounter heightened developmental risks and regulatory scrutiny when introducing new antifungal agents.Validating the severity of this impediment, recent statistics reveal a concerning prevalence of resistant cases. According to the Centers for Disease Control and Prevention (CDC), an estimated 19% of Aspergillus fumigatus infections in medical centers within certain regions in 2024 were resistant to azole antifungals. This substantial proportion of resistant infections directly hinders market expansion by rendering widely available treatments ineffective for a significant patient segment, consequently fragmenting the market and slowing the overall adoption of established therapeutic interventions.

Market Trends

The increasing adoption of rapid non-invasive diagnostic technologies is transforming clinical protocols by reducing the need for invasive procedures such as bronchoscopy and lung biopsies. Clinicians are progressively integrating urine-based antigen testing to accelerate time-to-diagnosis for invasive aspergillosis, particularly in patients with hematologic malignancies where swift diagnosis is crucial for survival. This technological advancement addresses the limitations of traditional culture methods and serum biomarkers, which often produce delayed or ambiguous results, by offering a patient-friendly alternative that facilitates earlier therapeutic intervention. Pearl Diagnostics' newly approved MycoMEIA Aspergillus Assay, cleared by the FDA in August 2025, demonstrated approximately 90% sensitivity in clinical validation, providing a precise non-invasive tool to enhance disease detection rates.Simultaneously, there is a notable shift toward prophylactic antifungal regimens aimed at preventing infections in high-risk transplant recipients before onset. Pharmaceutical companies are actively expanding the labels of long-acting echinocandins and other novel agents to include prevention in allogeneic blood and marrow transplant patients, moving beyond reactive treatment strategies. This proactive approach is driven by the substantial economic and clinical value of averting severe fungal episodes in immunocompromised hosts, thereby reducing hospital stays and systemic toxicity. CorMedix projected that peak annual sales for the antifungal rezafungin in its expanded prophylaxis indication could exceed $200 million following its acquisition of Melinta Therapeutics in August 2025, underscoring the market's strong focus on preventive care.

Key Market Players

• Pfizer Inc.
• Merck & Co., Inc.
• Astellas Pharma Inc.
• Gilead Sciences, Inc.
• Bayer AG
• Novartis AG
• Bristol-Myers Squibb Company
• Basilea Pharmaceutica Ltd.
• F2G Ltd.
• Mayne Pharma Group Ltd.

Report Scope

In this report, the Global Aspergillosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Aspergillosis Market, By Type

• Chronic Pulmonary Aspergillosis
• Allergic Bronchopulmonary Aspergillosis (ABPA)
• Invasive Aspergillosis

Aspergillosis Market, By Drug Type

• Isavuconazole
• Voriconazole
• Amphotericin-B
• Itraconazole
• Corticosteroids
• Posaconazole
• Others

Aspergillosis Market, By Route of Administration

• Oral
• Intravenous

Aspergillosis Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Aspergillosis Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Aspergillosis Market.

Available Customizations:

Global Aspergillosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Aspergillosis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Invasive Aspergillosis)
  • 5.2.2. By Drug Type (Isavuconazole, Voriconazole, Amphotericin-B, Itraconazole, Corticosteroids, Posaconazole, Others)
  • 5.2.3. By Route of Administration (Oral, Intravenous)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Aspergillosis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Aspergillosis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Aspergillosis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Aspergillosis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Aspergillosis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Aspergillosis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Aspergillosis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Aspergillosis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Aspergillosis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drug Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Aspergillosis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drug Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Aspergillosis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Aspergillosis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Aspergillosis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Aspergillosis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Aspergillosis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drug Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Aspergillosis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drug Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Aspergillosis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Aspergillosis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Aspergillosis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Aspergillosis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Aspergillosis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drug Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Aspergillosis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drug Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Aspergillosis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drug Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Aspergillosis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drug Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Aspergillosis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co., Inc.
• 15.3. Astellas Pharma Inc.
• 15.4. Gilead Sciences, Inc.
• 15.5. Bayer AG
• 15.6. Novartis AG
• 15.7. Bristol-Myers Squibb Company
• 15.8. Basilea Pharmaceutica Ltd.
• 15.9. F2G Ltd.
• 15.10. Mayne Pharma Group Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer